Interleukin-17 antagonist attenuates lung inflammation through inhibition of the ERK1/2 and NF-κB pathway in LPS-induced acute lung injury

  • Authors:
    • Tie‑Jun Li
    • Lian‑Li Zhao
    • Jing Qiu
    • Hai‑Yan Zhang
    • Guo‑Xin Bai
    • Liang Chen
  • View Affiliations

  • Published online on: June 21, 2017     https://doi.org/10.3892/mmr.2017.6837
  • Pages: 2225-2232
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Interleukin (IL)-17 has been implicated in a variety of inflammatory lung diseases. However, little is known about the expression and biological role of IL‑17 in acute lung injury (ALI). Therefore, the aim of the present study was to confirm whether the increase in IL‑17 expression following ALI enhances expression of inflammatory cytokines/chemokines through activation of the extracellular signal‑regulated kinase (ERK)1/2 and nuclear factor (NF)‑κB signaling pathway in lipopolysaccharide (LPS)‑induced acute lung injury; which, in turn, can be blocked by an IL‑17 antagonist. The authors indicated that levels of IL‑17 mRNA and protein were elevated in the bronchoalveolar lavage fluid (BALF) and lung tissues of ALI rats, and upregulation of IL‑17 resulted in the enhanced severity of lung injury. Moreover, treatment with an IL‑17 neutralizing antibody significantly inhibited the increases of parameters of ALI in rats, as evidenced by decreased histologic scores, BALF exudate volume, protein leakage and wet‑to‑dry weight ratio. In addition, management of IL‑17 may markedly mitigate LPS‑induced pulmonary inflammation, as reflected by the reduced levels of a multitude of proinflammatory cytokines in BALF. Of note, blockade of IL‑17 effectively inhibited LPS‑induced expression and activation of p‑ERK1/2 and nuclear factor (NF)‑κB p65 in lung tissues, and suppressed nuclear translocation of NF‑κB p65. These results indicated that IL‑17 serves an important role in LPS‑induced ALI via stimulation of the ERK1/2 and NF‑κB signaling pathway, and serves as a potential therapeutic target for treating LPS-induced ALI.
View Figures
View References

Related Articles

Journal Cover

August-2017
Volume 16 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li TJ, Zhao LL, Qiu J, Zhang HY, Bai GX and Chen L: Interleukin-17 antagonist attenuates lung inflammation through inhibition of the ERK1/2 and NF-κB pathway in LPS-induced acute lung injury. Mol Med Rep 16: 2225-2232, 2017
APA
Li, T., Zhao, L., Qiu, J., Zhang, H., Bai, G., & Chen, L. (2017). Interleukin-17 antagonist attenuates lung inflammation through inhibition of the ERK1/2 and NF-κB pathway in LPS-induced acute lung injury. Molecular Medicine Reports, 16, 2225-2232. https://doi.org/10.3892/mmr.2017.6837
MLA
Li, T., Zhao, L., Qiu, J., Zhang, H., Bai, G., Chen, L."Interleukin-17 antagonist attenuates lung inflammation through inhibition of the ERK1/2 and NF-κB pathway in LPS-induced acute lung injury". Molecular Medicine Reports 16.2 (2017): 2225-2232.
Chicago
Li, T., Zhao, L., Qiu, J., Zhang, H., Bai, G., Chen, L."Interleukin-17 antagonist attenuates lung inflammation through inhibition of the ERK1/2 and NF-κB pathway in LPS-induced acute lung injury". Molecular Medicine Reports 16, no. 2 (2017): 2225-2232. https://doi.org/10.3892/mmr.2017.6837